Agenda Released for Immunogenicity 2016: Accelerating Commercialisation of Your Next Gen Biotherapeutics

London, United Kingdom, February 19, 2016 --(PR.com)-- Biologics is a fast expanding area in the Pharmaceutical industry with growth rates 2 -3 times as fast as chemical entities.* With the global vaccine market expected to reach $84.44 billion by 2022, now is the time to engage with industry experts. Immunogenicity continues to be a major concern for the field of science, due to its impact on safety and efficacy. As such, immunogenicity assessment of a biopharmaceutical drug’s immunogenic potential remains at the forefront of drug development.

The 2016 event will address the real challenges with immunogenicity including assay assessment, the role of aggregation, the introduction of nanobodies and much more.

For further information or to register please visit the event website www.immuno.co.uk/prcom or contact Matthew Apps on +44 (0) 207 827 6093 or mapps@smi-online.co.uk

The 2016 Speaker Line-Up includes:

Chairs For 2016:
• Annie De Groot, CEO and CSO, EpiVax, Inc.
• Adnan Khan, Senior Scientist Immunology/Pharmacology, UCB

Featured Speakers:
• Meenu Wadhwa, Section Leader, Cytokines and Growth Factors, NIBSC, MHRA
• Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
• Daniel Sikkema, Executive Director, Head of Immunogenicity and Clinical Immunology, GlaxoSmithKline
• Jochem Gokemeijer, Associate Director, Bristol-Myers Squibb
• Tim Hickling, Immunogenicity Sciences Discipline Lead, Pfizer
• Kees Melief, Chief Scientific Officer, ISA Pharmaceuticals

To download the full agenda please visit the event website www.immuno.co.uk/prcom

Benefits Of Attending:
• Gain insight into how tackle the challenges involved with the assessment of early risks in immunogenicity
• Hear key feedback from regulatory authorities on how to increase your speed to market
• Participate in insightful discussions on; nanobodies, ADCs, biosimilars and much more.

There will be two interactive post-conference workshops running alongside the conference. The first workshop entitled ‘Approaches to standardising assays for measuring drug levels and anti-drug antibodies to biotherapeutics in clinical practice’ will be led by Hishani Kirby, Founder and Director, Hishani Kirby Associates Ltd and Daniel Sikkema, Executive Director, Head of Immunogenicity and Clinical Immunology, GlaxoSmithKline. The second workshop ‘Unwanted immunogenicity from bench to bedside’ will be led by Arno Kromminga, CEO/CSO, IPM Biotech and Sofie Pattijn, Chief Technology Officer, ImmunXperts.

To register or for further information on the workshop/leaders please visit the event website www.immuno.co.uk/prcom

For those interested in attending, there is currently an early bird offer available saving £400 off of the conference price which expires on the 31st March.

Immunogenicity 2016 is sponsored by Abzena

For sponsorship enquiries, contact Alia Malick on +44 (0) 207 827 6168 or amalick@smi-online.co.uk

For delegate enquiries, contact Matthew Apps on +44 (0) 207 827 6093 or mapps@smi-online.co.uk

For media enquiries, contact Anna Serazetdinova on +44 20 7827 6180 or aserazetdinova@smi-online.co.uk

3rd annual Immunogenicity conference
13-14 June 2016
London, UK
www.immuno.co.uk/prcom
Contact e-mail: aserazetdinova@smi-online.co.uk
Contact tel: +44 (0) 207 827 6093
#immunosmi
Source* http://bit.ly/1Qlh628

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk